Quinsam Capital (QCA) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
9 Jun, 2026Executive summary
Reported Q2 2024 net loss of $0.5 million ($0.005 per share), an improvement from a net loss of $0.9 million ($0.009 per share) in Q2 2023.
Net assets at June 30, 2024, were approximately $0.13 per share outstanding.
Shares continue to trade at a steep discount to NAV.
Q2 net loss mainly due to declines in two public company investments, with subsequent recovery in one post-quarter.
Financial highlights
Total more liquid investments (cash, public equities, derivatives) exceed $0.05 per share.
Q2 net loss primarily driven by valuation changes in California Nanotechnologies and Rivalry.
Outlook and guidance
Ongoing search for a value-creating transaction, with expectations that it may take time due to few new listings.
New investments are not expected to impact timing of any value-creating transaction.
Latest events from Quinsam Capital
- Q2 net loss narrowed, liquidity improved, and several IPOs are pending amid a cautious outlook.QCA
Q2 202510 Jun 2026 - Q4 outlook hinges on public listings and clinical milestones, with NAV poised for potential growth.QCA
Q3 202510 Jun 2026 - Q1 2025 net income fell to $0.2M; several private holdings near listing, shares below NAV.QCA
Q1 20259 Jun 2026 - Q3 profit surged to $1.2M on Cal Nano gains, Givex privatization, and cost cuts.QCA
Q3 20249 Jun 2026 - Q4 net loss increased to $4.3 million as portfolio provisions and market headwinds persisted.QCA
Q4 20249 Jun 2026 - Q1 net income and NAV surged, with mining gains and a major listing expected to drive growth.QCA
Q1 202620 May 2026 - Q4/2025 profit and NAV growth driven by strong investments; further gains expected in Q1/2026.QCA
Q4 202528 Apr 2026